Hepatic disease in injection drug users

Infectious Disease Clinics of North America

Volumn 16, Issue 3, 2002, Pages 667-679

  Lemberg, Brent D ^a   Shaw Stiffel, Thomas A ^a  

^a STRONG MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; COCAINE;

ALCOHOL CONSUMPTION; DELTA AGENT HEPATITIS; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS G; HUMAN; INTRAVENOUS DRUG ABUSE; LIFESTYLE; LIVER DISEASE; LIVER TRANSPLANTATION; REVIEW; VACCINATION; VIRUS HEPATITIS;

ADULT; HEPATITIS, VIRAL, HUMAN; HUMANS; PREVALENCE; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES;

EID: 0036738234     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(02)00014-4     Document Type: Review

References (42)

1. National Institute on Drug Abuse. National Institutes of Health. Nationwide trends: 13567. www.drugabuse.gov. Accessed: September 18, 2001.
2. Lemon S. The natural history of hepatitis A: the potential for transmission by transfusion of blood or blood products. Vox Sang 1994;67(Suppl):S19-25.
3. Centers for Disease Control. Changing patterns of groups at high risk for hepatitis B in the United States. MMWR Morb Mortal Wkly Rep 1988;37:429-32, 437.
4. Hutin Y, Sabin K, Hutwagner L, et al. Multiple modes of hepatitis A virus transmission among methamphetamine users. Am J Epidemiol 2000;152(2):186-93.
5. Willner I, Uhl M, Howard S, et al. Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann Intern Med 1998; 128:111.
6. Keefe E. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol 1995;90:201-3.
7. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286-90.
8. Befeler A, DiBisceglie A. Hepatitis B. Infectious Disease Clinics of North America 2000;14(3):617-30.
9. Bhandari B, Wright T. Viral hepatitis. In: Grendell J, McQuaid K, Freidman S, editors. Current diagnosis and treatment in gastroenterology. Stamford (CT): Appleton and Lange; 1996. p. 484-508.
10. Centers for Disease Control and Prevention. Public health service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B. MMWR Morb Mortal Wkly Rep 1991;40:1-17.
11. Lok A, Chan H. Viral hepatitis B and D. Comprehensive clinical hepatology. New York: Mosby-Year Book; July 2000.
12. Casey J. Hepatitis D virus. In: Schiff E, Hoofnagle J, editors. American Association for the study of Liver Diseases postgraduate course 2000: update on viral hepatitis. Dallas, TX, October 27-28.
13. Alter M. Epidemiology of hepatitis C. Hepatology 1997;26(Suppl):S62-5.
14. Alter M, Kruszon-Moran D, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341(8):556-62.
15. Vargas H, Wang L, Laskus T, et al. Distribution of infecting hepatitis C virus genotypes in end-stage liver disease patients at a large American transplantation center. J Infect Dis 1997;175(2):448-50.
16. Farci T, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa2a. N Engl J Med 1994;330(88).
17. Alter M, Mast E, Moyer L, et al. Hepatitis C. Infectious Disease Clinics of North America 1998;12:13-26.
18. Bell J, Batey R, Farrell G. Hepatitis C virus in intravenous drug users. Med J Aus 1990;153:274-95.
19. Cheney C, Chopra A, Graham C. Hepatitis C. Infectious Disease Clinics of North America 2000;14(3):633-56.
20. Davis G, Albright J, Cook S, et al. Projecting the future healthcare burden from hepatitis C in the United States [abstract]. Hepatology 28(Suppl):390A.
21. Mitsui T, Iwano K, Masuko K, et al. Hepatitis C virus infection in medical personnel after a needle stick accident. Hepatology 1992;16:1109-14.
22. Backmund M, Meyer D, Von Zielonka M. Treatment of hepatitis C infection in injection drug users. Hepatology 2001;34(1):188-93.
23. Thomas D, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995;74(4):212-20.
24. Hagan H, Thiede H, Weiss N, et al. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Pub Health 2001;91(1):42-6.
25. Hahn J, Page-Shaffer K, Lum P, et al. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 2001; 34(1):180-7.
26. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127(10):875-81.
27. McHutchinson J, Gordon S, Schiff E, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
28. Zeuzem S, Feinman S, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
29. Muir A. An evaluation of eligibility of therapy among veterans with hepatitis C. Hepatology 1999;30(Suppl):A190.
30. Alter H, Jett B, Polito A, et al. Analysis of the role of hepatitis C in transfusion associated hepatitis. In: Hollinger F, Lemon S, Margois H, editors. Viral hepatitis and liver disease. Baltimore, MD: Williams and Wilkins; 1991. p. 396-402.
31. Bjoro K, Froland S, Yun Z, et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331:1607-11.
32. Bodenheimer H, Lindsay K, Davis G, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology 1997;26:473-7.
33. Johnson M, Fisher D, Fenaughty A, et al. Hepatitis C virus and depression in drug users. Am J Gastroenterol 1998;93(5):785-7.
34. Wiley T, McCarthy M, Breidi L, et al. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998;28(3):805-9.
35. Jowett S, Agarwal K, Smith B, et al. Managing chronic hepatitis C acquired through intravenous drug use. QJM 2001;94:153-8.
36. Edlin B, Seal K, Lorvick J. Is it justifiable to withhold treatment for Hepatitis C from illicit-drug users? N Engl J Med 2001;345(3):211.
37. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-89.
38. DiBisceglie A. Hepatitis G virus infection: A work in progress. Ann Intern Med 1996; 125(9):772-3.
39. Reichard O, Norkrans G, Fryden A, et al. Randomized, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-6.
40. Diamantis I, Bassetti S, Erb P, et al. High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts. J Hepatol 1997;26:794-7.
41. Recommendation of the Immunization Practices Advisory Committee (ACIP). Inactivated hepatitis B virus vaccine. MMWR Morb Mortal Wkly Rep 1982;31:317-22, 327-28.
42. Keefe E, Iwarson S, McMahon B, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998;27:881-4.